This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0) license. This work is licensed under a Creative Commons ...

Debiopharm announces an abstract publication and three poster presentations on Debio 0123, a highly selective WEE1 inhibitor, in multiple solid tumor indications. LAUSANNE, Switzerland--(BUSINESS WIRE ...

BBI-355 and BBI-825 Programs Discontinuing current monotherapy and combination arms of BBI-355 in POTENTIATE clinical trial Boundless has been investigating BBI-355, a novel, oral, selective CHK1 ...

Heart failure is the final outcome of most cardiovascular diseases and shares risk factors with other cardiovascular pathologies. Among these, inflammation plays a central role in disease progression ...